Navamedic ASA (NAVA) Fair Value & Analysis
Healthcare · NO · Market cap 423M NOK
Fair value as of: Jun 24, 2026
From 17 valuation models · updated 9 days ago
Share price −0.3% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 15.58 – kr 25.39 · fair‑value band kr 11.33 – kr 29.01 · the kr 16.35 price screens below the kr 19.40 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Navamedic ASA (NAVA) currently trades at kr 16.35, while our model-based Fair Value estimate is kr 19.40 — implying the stock looks roughly 18.7% undervalued today. We read business quality at 30/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Navamedic ASA generated revenue of 571M NOK at a net margin of -2.8%. Revenue grew 4.5% year over year. It earns a return on equity of -6.2%. Net debt stands at 152M NOK. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. Its product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. The company offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases, fat metabolism, renal, nutritional support, and ketogenic diet. In addition, it provides consumer health products consisting of non-prescription drugs and health care products for erectile dysfunction, pain, gastro-related problems, and others primarily through pharmacies and drugstores; prescription medicines …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Navamedic ASA reported revenue of kr 565M in FY2025 versus kr 278M in FY2021, a compound +19.4%/yr. Reported net income was −kr 23.5M in FY2025.
Is NAVA fairly valued? → Check now
Similar stocks
6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation M1CK34 | R$958.36 | R$188.90 | -80% |
| Cencora, Inc C1CO34 | R$709.32 | R$400.31 | -44% |
| Cardinal Health, Inc CAH | $222.74 | $141.77 | -36% |
| Sigma Healthcare Limited SIGGF | $2.35 | $0.7800 | -67% |
| Shanghai Pharmaceuticals Holding 601607 | ¥15.96 | ¥45.15 | +183% |
| Henry Schein, Inc HSIC | $76.30 | $53.31 | -30% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Navamedic ASA (NAVA) undervalued?
What is the fair value of NAVA?
What is the quality score of NAVA?
What is the revenue of Navamedic ASA (NAVA)?
What is the net profit margin of NAVA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.